Post COVID interstitial lung diseases syndrome: diagnosis and management as interstitial lung disease?

Pro-Con debate
Chairs: K. Antoniou (Heraklion, Greece), M. Kreuter (Heidelberg, Germany)
Aims: To describe the spectrum of interstitial lung changes observed after COVID-19 infection, and to address diagnostic and management related issues; to debate the use or not corticosteroids plus antifibrotics and/or immunomodulation according pathogenetic and clinical/radiological insights in the field. to discuss clinical, radiological and pathological description of post COVID-19 interstitial lung cases.

Use of antifibrotics in post-COVID ILD: PRO B. Crestani (Paris, France)
Use of antifibrotics in post-COVID ILD: CON S. Tomassetti (Florence, Italy)
Discussion and Q&A